Author

G. Meier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Approach:deep learning· 2 Assay:structural biology· 2 Assay:ATAC-seq· 1 Organism:bacteria (other)· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

C. A. J. Hutter· 3 shared M. A. Seeger· 3 shared S. Thavarasah· 3 shared I. Gonda· 2 shared I. Zimmermann· 2 shared J. D. Walter· 2 shared L. M. Hürlimann· 2 shared M. Sorgenfrei· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

C. A. J. Hutter

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Deep mutational scan of a drug efflux pump reveals its structure-function landscape

G. Meier, S. Thavarasah, K. Ehrenbolger, C. A. J. Hutter, L. M. Hürlimann, J. Barandun, M. A. Seeger

The paper uses deep mutational scanning to analyze the structure-function relationship of the EfrCD drug efflux pump, revealing how mutations affect drug efflux and identifying mutations that convert it into a drug importer.

bioRxiv · Oct 1, 2021Biochemistry

Biparatopic sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug resistance

J. D. Walter, C. A. J. Hutter, A. A. Garaeva, M. Scherer, I. Zimmermann, M. Wyss, J. Rheinberger, Y. Ruedin, J. C. Earp, P. Egloff, M. Sorgenfrei, L. Hürlimann, I. Gonda, G. Meier, S. Remm, , M. A. Seeger

bioRxiv · Nov 10, 2020Biochemistry

Sybodies targeting the SARS-CoV-2 receptor-binding domain

J. D. Walter, C. A. J. Hutter, I. Zimmermann, M. Wyss, P. Egloff, M. Sorgenfrei, L. M. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, P. Plattet, M. A. Seeger

This paper reports the rapid in vitro selection of sybodies targeting the SARS-CoV-2 receptor-binding domain, identifying potent inhibitors with ACE2 blocking activity and potential for therapeutic development.

bioRxiv · Apr 16, 2020 · PreprintBiochemistry